Literature DB >> 15706234

Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition.

Mendell Rimer1, Douglas W Barrett, Monica A Maldonado, Vita M Vock, F Gonzalez-Lima.   

Abstract

Genetic and behavioral studies in humans and mouse mutants have implicated the gene encoding neuregulin-1 (Nrg-1) as a candidate susceptibility gene for schizophrenia. We examined the behavior of mice heterozygous for a mutation in neuregulin-1's immunoglobulin (Ig)-like domain (Ig-nrg-1 mice). We found that these animals displayed behaviors related to a schizophrenia-like phenotype, such as clozapine suppression of open-field and running wheel activity and impaired latent inhibition. Contrary to findings with other nrg-1 mutants, Ig-nrg-1 mice did not exhibit significantly elevated locomotion relative to littermate controls. These results suggest that Ig-Nrg-1's contribute to some - but not all - aspects of the schizophrenia-like phenotype of nrg-1 mutants, and further support nrg-1 as a candidate gene for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706234     DOI: 10.1097/00001756-200502280-00014

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  45 in total

Review 1.  Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.

Authors:  Christina Wilson; Alvin V Terry
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-07

Review 2.  Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?

Authors:  Craig M Powell; Tsuyoshi Miyakawa
Journal:  Biol Psychiatry       Date:  2006-06-15       Impact factor: 13.382

3.  Disruption of the neuregulin 1 gene in the rat alters HPA axis activity and behavioral responses to environmental stimuli.

Authors:  S B Taylor; A R Taylor; J A Markham; A M Geurts; B Z Kanaskie; J I Koenig
Journal:  Physiol Behav       Date:  2010-11-16

4.  Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components.

Authors:  Ying-Jiun J Chen; Madeleine A Johnson; Michael D Lieberman; Rose E Goodchild; Scott Schobel; Nicole Lewandowski; Gorazd Rosoklija; Ruei-Che Liu; Jay A Gingrich; Scott Small; Holly Moore; Andrew J Dwork; David A Talmage; Lorna W Role
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

5.  Sex-specific neuroendocrine and behavioral phenotypes in hypomorphic Type II Neuregulin 1 rats.

Authors:  Sara B Taylor; Julie A Markham; Adam R Taylor; Brooke Z Kanaskie; James I Koenig
Journal:  Behav Brain Res       Date:  2011-05-19       Impact factor: 3.332

Review 6.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

7.  Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene.

Authors:  J D Buxbaum; L Georgieva; J J Young; C Plescia; Y Kajiwara; Y Jiang; V Moskvina; N Norton; T Peirce; H Williams; N J Craddock; L Carroll; G Corfas; K L Davis; M J Owen; S Harroch; T Sakurai; M C O'Donovan
Journal:  Mol Psychiatry       Date:  2007-04-17       Impact factor: 15.992

8.  Physiological and behavioral effects of amphetamine in BACE1(-/-) mice.

Authors:  R Madelaine Paredes; E Piccart; E Navaira; D Cruz; M A Javors; W Koek; M J Beckstead; C Walss-Bass
Journal:  Genes Brain Behav       Date:  2015-05-21       Impact factor: 3.449

Review 9.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

10.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

Authors:  Lei Wen; Yi-Sheng Lu; Xin-Hong Zhu; Xiao-Ming Li; Ran-Sook Woo; Yong-Jun Chen; Dong-Min Yin; Cary Lai; Alvin V Terry; Almira Vazdarjanova; Wen-Cheng Xiong; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.